Nadera Sweiss, MD
Rheumatology · Burr Ridge, ILNPI 1124181649
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 69.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,815 and has fallen 84.0% since, to $451 in 2025.
Across 41 payments — averaging $101.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$336
- Argenx US, Inc.$329
- Johnson & Johnson$112
- Mallinckrodt Hospital Products Inc.$93
- Pfizer$90
- plus $297 from 6 others
Across 3 payments — averaging $8573.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$23K
- Bristol Myers Squibb$2K
What the payments were for
- Consulting fees$2,40058%
- Food & beverage$1,71241%
- Education$601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $2,915 |
| Amgen | 6 | $336 |
| Argenx US, Inc. | 6 | $329 |
| Johnson & Johnson | 3 | $112 |
| Mallinckrodt Hospital Products Inc. | 2 | $93 |
| Pfizer | 4 | $90 |
| Mallinckrodt Enterprises LLC | 1 | $90 |
| GSK | 4 | $78 |
| UCB, Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Novo Nordisk | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$231
- Rinvoq$125
- VYVGART HYTRULO$124
- Skyrizi$106
How this compares
$4,172 in reported general payments places this provider in the 70th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $468,035 |
| Humira PenAdalimumab | 33 | $346,652 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $229,402 |
| RemicadeInfliximab | 20 | $115,209 |
| Xeljanz XrTofacitinib Citrate | 11 | $63,479 |
| Actemra ActpenTocilizumab | 13 | $54,028 |
| Ambrisentan | 12 | $34,200 |
| Mycophenolate Mofetil | 82 | $24,038 |
| RasuvoMethotrexate/Pf | 13 | $9,816 |
| Hydroxychloroquine Sulfate | 106 | $3,505 |
| MethotrexateMethotrexate Sodium | 91 | $2,573 |
| Azathioprine | 60 | $2,474 |
| Leflunomide | 41 | $2,266 |
| Leucovorin Calcium | 44 | $1,516 |
| Methylprednisolone | 98 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $90 | $229,40216 claims |
| Johnson & JohnsonRemicade | $112 | $115,20920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Burr Ridge
- Michael BeckerBurr Ridge$22K
- Manish JainChicago$1.9M
- Lori SiegelBannockburn$1.5M
- Alfonso BelloGlenview$611K
- Theodore PincusChicago$524K
- Angela CrowleyWillowbrook$483K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Jeffrey HorvathSpringfield$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.